Generate Biomedicines, Inc.

Filing Date

Feb 26, 2026

Transaction Date

Feb 26, 2026

Accession Number

0001193125-26-078483

Form Type

3

Footnotes

1. (F1)The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
2. (F2)Each share of Series A Preferred Stock is convertible into Common Stock on a one-for-1.5190 basis at the option of the holder, and will convert automatically upon the closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration. The Series A Preferred Stock has no expiration date.
3. (F3)The shares underlying this option are fully vested and exercisable.
4. (F4)The shares underlying this option vest in sixteen equal quarterly installments following September 1, 2023, subject to the Reporting Person's continued service on each such vesting date.
5. (F5)The shares underlying this option vest in sixteen equal quarterly installments following January 3, 2024, subject to the Reporting Person's continued service on each such vesting date.
6. (F6)25% of the shares underlying this option shall vest on March 1, 2026 with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.